



MEN

## FIRST CANCER SITE

## BRAIN AND CENTRAL NERVOUS SYSTEM

BRAIN AND CENTRAL NERVOUS SYSTEM  
POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

ENCEFALO E SISTEMA NERVOSO CENTRALE  
POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	11743		14088		14088		11743		5442		1552		611		11743	14088
Person-years ▶	25033		27186		2152		6657		10293		5110		2973		25033	27186
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND BRAIN AND CNS	160	0.82	218	0.97	58	1.96	55	0.77	47	0.67	37	1.10	21	1.03	-1.41	-1.41
HEAD AND NECK	11	1.09	11	0.95	0	0.00	2	0.54	4	1.07	3	1.76	2	2.11	0.04	0.04
ORAL CAVITY	3	1.22	3	1.08	0	0.00	1	1.14	1	1.10	1	2.35	0	0.00	0.02	0.02
PHARYNX	3	1.27	3	1.12	0	0.00	1	1.19	0	0.00	1	2.44	1	4.30	0.03	0.03
LARYNX	5	0.94	5	0.82	0	0.00	0	0.00	3	1.54	1	1.15	1	2.12	-0.01	-0.01
OESOPHAGUS	3	1.35	3	1.18	0	0.00	2	2.42	0	0.00	1	2.68	0	0.00	0.03	0.03
STOMACH	5	0.46	5	0.39	0	0.00	1	0.24	2	0.51	1	0.54	1	0.95	-0.24	-0.24
COLON RECTUM	21	0.80	26	0.86	5	1.25	7	0.73	8	0.86	6	1.32	0	0.00	-0.20	-0.20
COLON	16	0.91	20	0.99	4	1.48	7	1.10	4	0.65	5	1.64	0	0.00	-0.06	-0.06
RECTUM	5	0.58	6	0.61	1	0.77	0	0.00	4	1.30	1	0.67	0	0.00	-0.14	-0.14
LIVER	5	0.63	7	0.77	2	1.63	0	0.00	2	0.71	1	0.75	2	2.52	-0.12	-0.12
GALLBLADDER	3	1.61	3	1.38	0	0.00	1	1.43	0	0.00	1	3.14	1	5.27	0.05	0.05
PANCREAS	1	0.20	1	0.17	0	0.00	0	0.00	0	0.00	1	1.14	0	0.00	-0.16	-0.16
LUNG	19	0.56	40	1.01	21	3.88	9	0.69	5	0.41	3	0.53	2	0.61	-0.60	-0.60
SKIN MELANOMA	5	1.29	7	1.63	2	4.55	3	2.48	1	0.69	0	0.00	1	2.10	0.05	0.05
MESOTHELIOMA	1	0.97	1	0.85	0	0.00	1	2.66	0	0.00	0	0.00	0	0.00	0.00	0.00
KAPOSI SARCOMA	6	11.51	6	10.17	0	0.00	4	23.27	2	10.06	0	0.00	0	0.00	0.22	0.22
SOFT TISSUE	1	1.12	1	1.00	0	0.00	1	3.47	0	0.00	0	0.00	0	0.00	0.00	0.00
BONE	1	3.27	1	2.95	0	0.00	0	0.00	1	8.34	0	0.00	0	0.00	0.03	0.03
BREAST	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
PROSTATE	29	0.85	38	0.96	9	1.68	6	0.47	4	0.34	11	1.85	8	2.07	-0.21	-0.21
TESTIS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.05	-0.05
KIDNEY AND RENAL PELVIS	6	0.87	10	1.28	4	4.21	4	1.65	1	0.40	1	0.83	0	0.00	-0.03	-0.03
BLADDER AND URINARY TRACT	7	0.33	10	0.40	3	0.89	5	0.63	2	0.26	0	0.00	0	0.00	-0.57	-0.57
URINARY BLADDER	7	0.34	10	0.42	3	0.93	5	0.65	2	0.27	0	0.00	0	0.00	-0.54	-0.54
URINARY TRACT	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
BRAIN AND CENTRAL NERVOUS SYSTEM	1	0.33	2	0.59	1	2.58	0	0.00	0	0.00	1	1.85	0	0.00	-0.08	-0.08
THYROID	5	3.06	6	3.35	1	6.27	2	4.22	1	1.59	0	0.00	2	9.58	0.13	0.13
HODGKIN LYMPHOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
NON-HODGKIN LYMPHOMA	6	0.92	7	0.95	1	1.15	2	0.90	4	1.66	0	0.00	0	0.00	-0.02	-0.02
MYELOMA	2	0.81	3	1.05	1	2.59	1	1.10	0	0.00	1	2.35	0	0.00	-0.02	-0.02
LEUKAEMIAS	8	1.71	13	2.42	5	7.17	1	0.60	4	2.33	2	2.42	1	2.11	0.13	0.13
LYMPHOID LEUKAEMIAS	2	0.87	7	2.65	5	14.72	1	1.21	1	1.18	0	0.00	0	0.00	-0.01	-0.01
MYELOID LEUKAEMIAS	6	2.88	6	2.51	0	0.00	0	0.00	3	3.94	2	5.38	1	4.49	0.16	0.16
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
OTHER AND ILL DEFINED SITES	15	1.53	19	1.67	4	2.63	3	0.84	6	1.70	5	2.91	1	0.98	0.21	0.21

Decrease/Difetto  
Increase/Eccesso

O Observed cases  
Casi osservati

SIR Standardized Incidence Ratio  
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk  
Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE

## BRAIN AND CENTRAL NERVOUS SYSTEM

BRAIN AND CENTRAL NERVOUS SYSTEM  
POOL AIRTUM 1976-2010, WOMEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

ENCEFALO E SISTEMA NERVOSO CENTRALE  
POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
	No. of subjects alive at interval beginning ▶	9778	11968		11968		9778		4419		1375		600		9778	11968
Person-years ▶	22049	23869		1820		5350		8921		4690		3087		22049	23869	
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND BRAIN AND CNS	110	0.87	144	1.01	34	2.08	26	0.66	41	0.86	27	1.15	16	0.98	-0.74	0.05
HEAD AND NECK	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.08	-0.08
ORAL CAVITY	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
PHARYNX	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
LARYNX	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
OESOPHAGUS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
STOMACH	5	0.83	6	0.86	1	1.04	0	0.00	3	1.35	2	1.88	0	0.00	-0.05	-0.04
COLON RECTUM	12	0.69	16	0.81	4	1.60	3	0.53	3	0.47	3	0.96	3	1.37	-0.24	-0.16
COLON	6	0.49	8	0.57	2	1.12	1	0.25	1	0.22	2	0.91	2	1.28	-0.28	-0.25
RECTUM	6	1.18	8	1.37	2	2.77	2	1.21	2	1.06	1	1.09	1	1.57	0.04	0.09
LIVER	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.13	-0.14
GALLBLADDER	1	0.44	1	0.38	0	0.00	1	1.33	0	0.00	0	0.00	0	0.00	-0.06	-0.07
PANCREAS	1	0.25	2	0.43	1	1.59	0	0.00	1	0.69	0	0.00	0	0.00	-0.14	-0.11
LUNG	9	1.27	12	1.48	3	2.98	4	1.73	3	1.16	1	0.78	1	1.08	0.09	0.16
SKIN MELANOMA	3	0.96	3	0.87	0	0.00	0	0.00	2	1.67	0	0.00	1	2.13	-0.01	-0.02
MESOTHELIOMA	1	3.37	1	2.95	0	0.00	0	0.00	0	0.00	0	0.00	1	25.74	0.03	0.03
KAPOSI SARCOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
SOFT TISSUE	0	0.00	1	1.48	1	14.20	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	0.01
BONE	0	0.00	1	4.37	1	47.51	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	0.03
BREAST	21	0.55	29	0.69	8	1.86	6	0.53	8	0.55	5	0.70	2	0.40	-0.77	-0.55
CERVIX UTERI	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.11	-0.11
CORPUS UTERI	9	1.39	9	1.23	0	0.00	1	0.49	3	1.23	4	3.39	1	1.23	0.11	0.07
OVARY	7	1.58	7	1.41	0	0.00	1	0.73	3	1.78	1	1.22	2	3.62	0.12	0.09
KIDNEY AND RENAL PELVIS	7	2.44	7	2.15	0	0.00	4	4.33	3	2.83	0	0.00	0	0.00	0.19	0.16
BLADDER AND URINARY TRACT	2	0.49	3	0.64	1	1.65	1	0.74	0	0.00	0	0.00	1	1.91	-0.10	-0.07
URINARY BLADDER	1	0.26	2	0.45	1	1.77	1	0.79	0	0.00	0	0.00	0	0.00	-0.13	-0.10
URINARY TRACT	1	3.93	1	3.39	0	0.00	0	0.00	0	0.00	0	0.00	1	31.50	0.03	0.03
BRAIN AND CENTRAL NERVOUS SYSTEM	0	0.00	1	0.44	1	3.91	0	0.00	0	0.00	0	0.00	0	0.00	-0.09	-0.05
THYROID	8	1.99	10	2.31	2	6.30	0	0.00	3	1.91	4	4.72	1	1.59	0.18	0.24
HODGKIN LYMPHOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
NON-HODGKIN LYMPHOMA	8	1.71	9	1.70	1	1.63	2	1.36	3	1.72	2	2.32	1	1.65	0.15	0.16
MYELOMA	1	0.52	6	2.70	5	17.56	0	0.00	1	1.41	0	0.00	0	0.00	-0.04	0.16
LEUKAEMIAS	6	2.03	8	2.37	2	4.86	2	2.15	2	1.79	2	3.67	0	0.00	0.14	0.19
LYMPHOID LEUKAEMIAS	4	3.10	6	4.07	2	10.81	2	4.80	1	2.05	1	4.28	0	0.00	0.12	0.19
MYELOID LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.06	-0.07
OTHER LEUKAEMIAS	2	8.49	2	7.39	0	0.00	0	0.00	1	11.33	1	22.34	0	0.00	0.08	0.07
OTHER AND ILL DEFINED SITES	9	1.14	13	1.43	4	3.42	1	0.40	3	1.02	3	2.05	2	1.96	0.05	0.16

Decrease/Difetto  
Increase/Eccesso

O Observed cases  
Casi osservati

SIR Standardized Incidence Ratio  
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk  
Eccesso assoluto di rischio